Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: An open-label study

Human Psychopharmacology

Volumn 26, Issue 2, 2011, Pages 155-160

  Mahmoudi Gharaei, Javad ^a   Dodangi, Nasrin ^a   Tehrani Doost, Mehdi ^a   Faghihi, Toktam ^b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ADHD; adolescents; duloxetine; hyperactivity; inattention; SNRI

Indexed keywords

DULOXETINE;

ADOLESCENT; ADULT; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONNERS PARENT RATING SCALE REVISED; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; NERVOUSNESS; OPEN STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADOLESCENT; AGE FACTORS; APPETITE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; HUMANS; NAUSEA; SELF REPORT; THIOPHENES; TREATMENT OUTCOME;

EID: 79956273891     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1188     Document Type: Article

References (33)

1. APA. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR). American Psychiatric Association: Washington, DC.
2. Carter NJ, McCormack PL,. 2009. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 23: 523-541.
3. Conners CK, Barkley RA,. 1985. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 21: 809-843.
4. Conners CK, Sitarenios G, Parker JDA, Epstein JN,. 1998. The revised Conners' parent rating scale (CPRS-R): factor structure, reliability and criterion validity. J Abnorm Child Psychol 26: 257-268. (Pubitemid 28359774)
5. Davanzo P, Kerwin L, Nikore V, Esparza C, Forness S, Murrelle L,. 2004. Spanish translation and reliability testing of the child depression inventory. Child Psychiatry Hum Dev 35: 75-92. (Pubitemid 39179620)
6. DellAgnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A,. 2009. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 23: 739-753.
7. Desarkar P, Das A, Sinha VK,. 2006. Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry 15: 496-499. (Pubitemid 46020534)
8. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA,. 2002. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63: 308-315. (Pubitemid 34456358)
9. Findling RL, Greenhill LL, McNamara NK, et al., 2007. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17: 433-446.
10. Frigerio A, Pesenti S, Molteni M, Snider J, Battaglia M,. 2001. Depressive symptoms as measured by the CDI in a population of northern Italian children. Eur Psychiatry 16: 33-37. (Pubitemid 32171330)
11. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L,. 2007. A retrospective pooled analysis of duloxetine safety in 23 983 subjects. Curr Med Res Opin 23: 175-184. (Pubitemid 46191681)
12. Garnock-Jones KP, Keating GM,. 2009. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11: 203-226.
13. Green WH,. 2007. Child and Adolescent Clinical Psychopharmacology. Wolters Kluwer: New York.
14. Gupta S, Nihalani N, Masand P,. 2007. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry 19: 125-132. (Pubitemid 47035939)
15. Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D,. 2009. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat 5: 215-226.
16. Khan AY, Macaluso M,. 2009. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat 5: 23-31.
17. Kovacs M,. 1985. The children's depression inventory. Psychopharmacol Bull 21: 995-998.
18. Leonard BE, McCartan D, White J, King DJ,. 2004. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol Clin Exp 19: 151-180. (Pubitemid 38514828)
19. Meighen KG,. 2007. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J Child Adolesc Psychopharmacol 17: 121-127. (Pubitemid 46452088)
20. Michelson D, Faries D, Wernicke J, et al., 2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose response study. Pediatrics 108: 1-9.
21. Michelson D, Allen AJ, Busner J, et al., 2002. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901. (Pubitemid 35283256)
22. Mukaddes NM, Abali O,. 2004. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci 58: 92-95. (Pubitemid 38200378)
23. Niederhofer N,. 2010. First preliminary results of a single case report: duloxetine might improve some symptoms of attention-deficit hyperactivity disorder. Eur Psychiatry 25: 214-215.
24. Olvera RL, Pliszka SR, Luh J, Tatum R,. 1996. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 6: 241-250.
25. Paykina N, Greenhill L,. 2008. Attention-Deficit/Hyperactivity Disorder. In Clinical Manual of Child and Adolescent Psychopharmacology, Findling RL, (ed). American Psychiatric Publishing: Washington; 33-97.
26. Pliszka S, AACAP Work Group on Quality Issues. 2007. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46: 894-921.
27. Rajabi GHR,. 2007. An investigation of reliability and validity of the child depression inventory in 13 to 15year old adolescents. J Psychol Education 37: 23-46.
28. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P,. 2005. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 44: 428-433. (Pubitemid 40559690)
29. Reynolds CR, Richmond BO,. 1997. What I think and feel: a revised measure of children's manifest anxiety. J Abnorm Child Psychol 25: 15-20. (Pubitemid 27137488)
30. Taghavi SMR,. 2005. The normalization of revised children's manifest anxiety scale (RCMAS) for students in Shiraz. J Social Sciences Hum Shiraz 22: 179-188.
31. Tourjman SV, Bilodeau M,. 2009. Improvement with duloxetine in an adult ADHD patient. J Atten Disord 13: 95-96.
32. Wernicke J, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L,. 2005. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 4: 987-993. (Pubitemid 41671597)
33. Wernicke J, Liedo A, Raskin J, Kajdasz DK, Wang F,. 2007. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 30: 437-455. (Pubitemid 46740340)